Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the KAMILLA trial and the benefit of trastuzumab emtansine.
Rachel Wuerstein, MD, of the Unïversität Müchen, discusses future implications of the KAMILLA trial (NCT01702571) as well as the benefit of trastuzumab emtansine (T-DM1).
The KAMILLA trial was created to look at the safety and efficacy of T-DM1 in metastatic breast cancer for both a global and Asian cohort. Some differences highlighted in the trial included the rate of thrombocytopenia and dose reductions.
Results from the exploratory analysis of T-DM1 in the KAMILLA trial showed patients with HER2-positive locally or advanced metastatic breast cancer who have brain metastases to have promising activity and tolerability on the therapy.
In addition, the safety and efficacy of T-DM1 was shown as no new safety signals were demonstrated in the trial.
0:08 | There is a variety of new tracks coming in trials, but also in an off-label setting in HER2-positive metastatic breast cancer. We think T-DM1 plays a major role in this setting and is one of the main factors to prolong survival of our patients with metastatic disease. What’s going to be interesting in the near future is to see how will track combinations be working, and I already pointed out this fact: How are we going to sequence our therapies in this continuously changing field of treatment of early but also metastatic breast cancer? I’m looking forward to seeing these data in individualized sequencing of the new tracks in the field of HER2-positive metastatic breast cancer. But again, [until that time], globally T-DM1 is the second-line standard of care in HER2-positive metastatic breast cancer.